Activation of angiotensin type 2 receptors partially ameliorates streptozotocin-induced diabetes in male rats by islet protection

Endocrinology

Volumn 155, Issue 3, 2014, Pages 790-804

  Shao, Chunhong ^a   Yu, Li ^a   Gao, Lie ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; CASPASE 3; COMPOUND 21; COPPER ZINC SUPEROXIDE DISMUTASE; GLUCOSE; GLYCOPROTEIN GP 91; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; MESSENGER RNA; PROINSULIN; PROINSULIN 2; PROTECTIVE AGENT; STREPTOZOCIN; SUPEROXIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; WATER; ANTIOXIDANT; CASP3 PROTEIN, RAT; CYBB PROTEIN, RAT; MEMBRANE PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CELL PROTECTION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; EPIDIDYMIS FAT; FLUID INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN SYNTHESIS; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OSMOTIC MINIPUMP; OXIDATIVE STRESS; PANCREAS ISLET CELL; PRIORITY JOURNAL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; URINARY EXCRETION; ANIMAL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; METABOLISM; ORAL DRUG ADMINISTRATION; PANCREAS ISLET; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CASPASE 3; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE TOLERANCE TEST; INSULIN; ISLETS OF LANGERHANS; MALE; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA, MESSENGER; STREPTOZOCIN;

EID: 84896859922     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1601     Document Type: Article

References (58)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
2. Wright JW, Harding JW. Brain renin-angiotensin-a new look at an old system. Prog Neurobiol. 2011;95:49-67.
3. Leung PS, Chappell MC. A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol. 2003; 35:838-846. (Pubitemid 36379325)
4. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12:70-88. (Pubitemid 36700689)
5. Wang L, Leung PS. The role of renin-angiotensin system in cellular differentiation: implications in pancreatic islet cell development and islet transplantation. Mol Cell Endocrinol. 2013;381:261-271.
6. Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves β-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes. 2006;55:367-374. (Pubitemid 43343265)
7. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes. 2004;53:989-997. (Pubitemid 38436611)
8. Yu L, Zheng M, Wang W, Rozanski GJ, Zucker IH, Gao L. Developmental changes in AT1 and AT2 receptor-protein expression in rats. J Renin Angiotensin Aldosterone Syst. 2010;11:214-221.
9. Yu L, Shao C, Gao L. Developmental expression patterns for angiotensin receptors in mouse skin and brain. J Renin Angiotensin Aldosterone Syst. 2013;14(3):255-262.
10. Gao J, Chao J, Parbhu KJ, et al. Ontogeny of angiotensin type 2 and type 1 receptor expression in mice. J Renin Angiotensin Aldosterone Syst. 2012;13:341-352.
11. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000;35:155-163. (Pubitemid 30054167)
12. Hilliard LM, Jones ES, Steckelings UM, Unger T, Widdop RE, Denton KM. Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension. Hypertension. 2012;59:409-414.
13. Gao L, Wang WZ, Wang W, Zucker IH. Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure. Hypertension. 2008;52:708-714.
14. Shao C, Zucker IH, Gao L. Angiotensin type 2 receptor in pancreatic islets of adult rats: a novel insulinotropic mediator. Am J Physiol Endocrinol Metab. 2013;305(10):E1281-E191.
15. Chappell MC, Diz DI, Jacobsen DW. Pharmacological characterization of angiotensin II binding sites in the canine pancreas. Peptides. 1992;13:313-318.
16. Chappell MC, Bosch SM, Hansen BC, Ferrario CM, Diz DI. Differential expression of AT2 angiotensin II receptors in the primate pancreas. J Hypertension. 1994;12:S181.
17. Ran J, Hirano T, Adachi M. Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab. 2004;287:E955-E961. (Pubitemid 39382933)
18. Chhabra KH, Xia H, Pedersen KB, Speth RC, Lazartigues E. Pancreatic angiotensin-converting enzyme 2 improves glycemia in angiotensin II-infused mice. Am J Physiol Endocrinol Metab. 2013; 304:E874-E884.
19. Mitsuishi M, Miyashita K, Muraki A, Itoh H. Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes. 2009;58:710-717.
20. Buchanan TA, Thawani H, Kades W, et al. Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. J Clin Invest. 1993;92:720-726. (Pubitemid 23262390)
21. Ramracheya RD, Muller DS, Wu Y, et al. Direct regulation of insulin secretion by angiotensin II in human islets of Langerhans. Diabetologia. 2006;49:321-331. (Pubitemid 43185401)
22. Siebelmann M, Wensing J, Verspohl EJ. The impact of ANG II and IV on INS-1 cells and on blood glucose and plasma insulin. J Recept Signal Transduct Res. 2010;30:234-245.
23. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008. (Pubitemid 39507341)
24. Unger T, Dahlof B. Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential. J Renin Angiotensin Aldosterone Syst. 2010;11:75-77.
25. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59:291-299.
26. Namsolleck P, Boato F, Schwengel K, et al. AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis. 2013;51:177-191.
27. Van Dyke K, Jabbour N, Hoeldtke R, Van Dyke C, Van Dyke M. Oxidative/nitrosative stresses trigger type I diabetes: preventable in streptozotocin rats and detectable in human disease. Ann NY Acad Sci. 2010;1203:138-145.
28. Van Dyke K, Ghareeb E, Van Dyke M, Sosa A, Hoeldtke RD, Van Thiel DH. Luminescence experiments involved in the mechanism of streptozotocin diabetes and cataract formation. Luminescence. 2008;23:386-391.
29. Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology. 2004;145:667-678. (Pubitemid 38183809)
30. Ohshima K, Mogi M, Jing F, et al. Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation. PLoS One. 2012;7:e48387.
31. Shum M, Pinard S, Guimond MO, et al. Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high-fat/high-fructose diet-induced insulin resistance in rats. Am J Physiol Endocrinol Metab. 2013;304:E197-E210.
32. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. J Endocrinol. 1999; 161:317-322. (Pubitemid 29244259)
33. Leung PS, Chan WP, Wong TP, Sernia C. Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol. 1999;160:13-19. (Pubitemid 29044563)
34. Chappell MC, Millsted A, Diz DI, Brosnihan KB, Ferrario CM. Evidence for an intrinsic angiotensin system in the canine pancreas. J Hypertens. 1991;9:751-759.
35. Skipworth JR, Szabadkai G, Olde Damink SW, Leung PS, Humphries SE, Montgomery HE. Review article: pancreatic renin-angiotensin systems in health and disease. Aliment Pharmacol Ther. 2011;34:840-852.
36. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766. (Pubitemid 37093915)
37. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031. (Pubitemid 38781102)
38. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
39. Devereux RB, Dahlof B, Kjeldsen SE, et al. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med. 2003;139:169-177.
40. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41:127-133. (Pubitemid 28088387)
41. Wiernsperger N. Vascular defects in the aetiology of peripheral insulin resistance in diabetes.Acritical review of hypotheses and facts. Diabetes Metab Rev. 1994;10:287-307. (Pubitemid 24306137)
42. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599-622. (Pubitemid 35191625)
43. Grankvist K, Marklund SL, Taljedal IB. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem J. 1981;199:393-398. (Pubitemid 12216744)
44. Steckelings UM, Larhed M, Hallberg A, et al. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol. 2011;11:187-192.
45. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523-2532.
46. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the nonpeptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159: 709-716.
47. Paulis L, Becker ST, Lucht K, et al. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension. 2012;59:485-492.
48. Gelosa P, Pignieri A, Fandriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444-2451.
49. Matavelli LC, Huang J, Siragy HM. Angiotensin AT(2) receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011;57:308-313.
50. Mertens B, Vanderheyden P, Michotte Y, Sarre S. Direct angiotensin II type 2 receptor stimulation decreases dopamine synthesis in the rat striatum. Neuropharmacology. 2010;58:1038-1044.
51. Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab. 2012;32:248-255.
52. Duran-Reyes G, Pascoe-Lira D, Vilar-Rojas C, et al. Diabetogenic effect of STZ diminishes with the loss of nitric oxide: role of ultraviolet light and carboxy-PTIO. Pharmacology. 2004;71:17-24. (Pubitemid 38410708)
53. Jimenez-Gonzalez M, Jaques F, Rodriguez S, et al. Cardiotrophin 1 protects β cells from apoptosis and prevents streptozotocin-induced diabetes in a mouse model. Diabetologia. 2013;56:838-846.
54. Palomar-Morales M, Morimoto S, Mendoza-Rodriguez CA, Cerbon MA. The protective effect of testosterone on streptozotocin-induced apoptosis in β cells is sex specific. Pancreas. 2010;39:193-200.
55. Dall'Aglio E, Chang H, Hollenbeck CB, Mondon CE, Sims C, Reaven GM. In vivo and in vitro resistance to maximal insulin-stimulated glucose disposal in insulin deficiency. Am J Physiol. 1985;249:E312-E316.
56. Shan T, Liu W, Kuang S. Fatty acid binding protein 4 expression marks a population of adipocyte progenitors in white and brown adipose tissues. FASEB J. 2013;27:277-287.
57. Melki SA, Abumrad NA. Expression of the adipocyte fatty acid-binding protein in streptozotocin-diabetes: effects of insulin deficiency and supplementation. J Lipid Res. 1993;34:1527-1534. (Pubitemid 23264325)
58. Iwai M, Tomono Y, Inaba S, et al. AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. Am J Hypertens. 2009;22:784-791.